<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21989" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Fulvestrant</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Farooq</surname>
            <given-names>Maheen</given-names>
          </name>
          <aff>Jinnah Hospital, Lahore</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Shivani P.</given-names>
          </name>
          <aff>L. M. College of Pharmacy</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maheen Farooq declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shivani Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21989.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Fulvestrant is used in the management and treatment of advanced breast cancer. It is a selective estrogen receptor degrader. This activity outlines the indications, action, and contraindications for fulvestrant as a valuable agent in the treatment of advanced breast carcinoma.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of fulvestrant.</p></list-item><list-item><p>Describe the possible adverse effects that may accompany therapy with fulvestrant.</p></list-item><list-item><p>Summarize the clinical benefit of fulvestrant in the treatment of breast cancer.</p></list-item><list-item><p>Explain the importance of collaboration and communication amongst the interprofessional team to ensure the appropriate selection of candidates for fulvestrant trials and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21989&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21989">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21989.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Fulvestrant has proven clinical benefit in HR-positive and HER2 negative breast cancer, predominantly in postmenopausal women.<xref ref-type="bibr" rid="article-21989.r1">[1]</xref>&#x000a0;Endocrine therapy is an important component of management in hormone-positive breast cancer as it is associated with better patient outcomes. Hormone-dependent tumors increase in size significantly in the presence of the corresponding hormone in the blood. This pathophysiology provides a potential avenue for treating these cancers. Since about 70 percent of all breast cancers are hormone receptor-positive, these endocrine agents are of utmost importance.</p>
        <p>Fulvestrant has been employed in patients with 'advanced' disease, including tumors of a very large size or those that metastasize heavily into the lymph nodes. It also includes tumors that have invaded the surrounding tissues and organs.<xref ref-type="bibr" rid="article-21989.r2">[2]</xref>&#x000a0;Since management at this stage mainly focuses on providing palliative care, the main objective of this modality of therapy is to improve survival, provide symptomatic improvement, and enhance the quality of life.&#x000a0;Fulvestrant is used in combination with several drugs for this purpose, e.g.,&#x000a0;ribociclib, palbociclib, alpelisib, etc.<xref ref-type="bibr" rid="article-21989.r3">[3]</xref><xref ref-type="bibr" rid="article-21989.r4">[4]</xref><xref ref-type="bibr" rid="article-21989.r5">[5]</xref></p>
      </sec>
      <sec id="article-21989.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Fulvestrant is a novel drug that has shown to be of some use in the management of advanced breast cancer. It acts by binding, blocking, and degradation of estrogen receptors, which in turn leads to the complete cessation of estrogen signaling through the estrogen receptors in the body.<xref ref-type="bibr" rid="article-21989.r6">[6]</xref>&#x000a0;Fulvestrant acts as a complete antagonist at the estrogen receptor, compared with the previously used drugs, namely the selective estrogen receptor modulators (SERMs), for example, tamoxifen, which had partial agonist activity. SERMs blocked the cellular E2 mediated activity of AF-2, which lead to inhibition of transcription downstream. However, they did not have enough AF-1 activity, which possibly leads to their partial agonist activity. Fulvestrant blocks both AF-1 and AF-2,&#x000a0;blocking the transcriptional activities of both downstream, and leaves no room for estrogen to exert its effects. Therefore, it is a complete antagonist at the estrogen receptor.<xref ref-type="bibr" rid="article-21989.r6">[6]</xref>&#x000a0;</p>
        <p>The novel drug has a high binding affinity for the estrogen receptor, almost 89% of estradiol.<xref ref-type="bibr" rid="article-21989.r6">[6]</xref>&#x000a0;It binds tightly with the estrogen receptor and inhibits the dimerization of the receptor, thus inhibiting its nuclear localization. This process forms an unstable nuclear complex, which degrades at a rapid pace and causes disintegration of the estrogen receptor itself. Consequently, in addition to its exclusively antagonistic actions at the estrogen receptor, Fulvestrant also causes accelerated degradation of the estrogen receptors throughout the body, leading to a decrease in cellular estrogen receptor&#x000a0;alpha levels and inhibiting estrogen signaling the estrogen receptor itself.<xref ref-type="bibr" rid="article-21989.r6">[6]</xref></p>
      </sec>
      <sec id="article-21989.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Fulvestrant is available in a pre-filled syringe of 250 mg per 5 mL.<xref ref-type="bibr" rid="article-21989.r7">[7]</xref></p>
        <p>
<bold>Dosing</bold>
</p>
        <p>For advanced, hormone receptor-positive breast cancer or hormone receptor-positive HER2-negative breast cancer: 500 mg IM, administered as two 5 mL injections, one in each buttock on days 1, 15, and 29, and subsequently once monthly.<xref ref-type="bibr" rid="article-21989.r7">[7]</xref></p>
        <p>For advanced or metastatic disease: Same dosing as above, in combination with ribociclib. If giving with palbociclib or ademaciclib, administer with an LHRH agonist in pre or perimenopausal patients.<xref ref-type="bibr" rid="article-21989.r7">[7]</xref></p>
        <p>In cases of moderate liver impairment, the recommendation is to reduce the dose to 250 mg.</p>
      </sec>
      <sec id="article-21989.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Fulvestrant is well-tolerated in most cases, according to multiple clinical trials. The most commonly encountered adverse effects were pain at the injection site and hot flashes. Other common side effects include headache, nausea, vomiting, loss of appetite, constipation, diarrhea, fatigue, abnormal liver function tests, urinary tract infections, and rashes.<xref ref-type="bibr" rid="article-21989.r8">[8]</xref>&#x000a0;In one case study, toxic epidermal necrolysis was observed in a woman with ductal carcinoma of the breast five days after the initiation of fulvestrant.<xref ref-type="bibr" rid="article-21989.r9">[9]</xref></p>
        <p>Another study reported vaginitis, weight gain, joint problems, and thromboembolic problems.<xref ref-type="bibr" rid="article-21989.r10">[10]</xref>&#x000a0;In a study investigating the role of&#x000a0;palbociclib&#x02013;fulvestrant in hormone-positive advanced breast carcinoma, various hematological side effects were reported, including neutropenia, thrombocytopenia, anemia, and leukemia.<xref ref-type="bibr" rid="article-21989.r5">[5]</xref>&#x000a0;Vulvovaginal dryness, pelvic pain, and vasomotor symptoms were observations in yet another study.<xref ref-type="bibr" rid="article-21989.r11">[11]</xref>&#x000a0;All of these side effects are comparable to the previously used endocrine medications such as anastrozole fused to treat breast cancer.&#x000a0;</p>
      </sec>
      <sec id="article-21989.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Fulvestrant is contraindicated in women who are pregnant or are breastfeeding. It is also associated with an increased bleeding risk in patients who have a clotting disorder and hence is not indicated in these patients. Low platelet count and liver diseases are also contraindications if present in any patient.<xref ref-type="bibr" rid="article-21989.r12">[12]</xref></p>
      </sec>
      <sec id="article-21989.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The monitoring of blood levels of fulvestrant is not indicated in most patients because, in its usual dosage, it is not known to cause significant adverse effects. No dose adjustment in renal or hepatic impairment is required, and it does not interact with cytochrome 3A4.<xref ref-type="bibr" rid="article-21989.r13">[13]</xref>&#x000a0;Regardless, efforts need to be put in this subject to find out the exact therapeutic index and the toxic dose of the medicine so that clinicians may have a sound protocol to administer the drug, even on a trial basis.</p>
      </sec>
      <sec id="article-21989.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>An overdose of fulvestrant is not overly likely as its administration must be by healthcare practitioners in a controlled environment. Thus the toxicity that results from the overdose of fulvestrant has not been reported in studies. However, more research is necessary regarding the development of a protocol in case such an event occurs.</p>
      </sec>
      <sec id="article-21989.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Breast cancer is the most common type of carcinoma in women (aside from skin cancers). Fulvestrant is one of the many medications employed in the treatment of breast carcinoma. All patients with breast cancer should be tested for hormone positivity to determine the role of endocrine therapy in their management. A team of healthcare professionals, which includes nurses, lab technologists, pharmacists, and physicians belonging to all related specialties, should coordinate and formulate the best treatment course appropriate for the stage of this type of cancer.&#x000a0;</p>
        <p>Interprofessional communication and care coordination will ensure improved&#x000a0;patient outcomes and hence should be encouraged and optimized. An essential aspect of the management of breast cancer is the selection of appropriate treatment modalities; this can be done by clinicians working with other healthcare providers to determine the receptor positivities of the particular tumor. Administration and management/monitoring should use nurses and pharmacists with specialized oncology training. In any case, all patients should receive counseling regarding the clinical benefit and possible toxicities of any medication that the interprofessional healthcare team deems suitable. This will optimize patient results with fewer adverse events. [Level 5]</p>
        <p>Multiple trials investigating the effect of fulvestrant in combination with other drugs in patients with hormone-positive breast carcinoma have shown promising results. There is evidence that the 500 mg dose is superior to the 250 mg dose used previously. However, more research is necessary to clarify these dosing parameters. The adverse effects reported are consistent with the side effects observed previously with other endocrine medications. Thus, the efficacy and safety of fulvestrant are well established.<xref ref-type="bibr" rid="article-21989.r14">[14]</xref>&#x000a0;[Level 1]</p>
      </sec>
      <sec id="article-21989.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21989&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21989">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21989/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21989">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21989.s11">
        <title>References</title>
        <ref id="article-21989.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bo&#x000e9;r</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Fulvestrant in advanced breast cancer: evidence to date and place in therapy.</article-title>
            <source>Ther Adv Med Oncol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>9</volume>
            <issue>7</issue>
            <fpage>465</fpage>
            <page-range>465-479</page-range>
            <pub-id pub-id-type="pmid">28717399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21989.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Goodwin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wilcken</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Fulvestrant for hormone-sensitive metastatic breast cancer.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Jan</month>
            <day>03</day>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>CD011093</fpage>
            <pub-id pub-id-type="pmid">28043088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21989.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markham</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Alpelisib: First Global Approval.</article-title>
            <source>Drugs</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>79</volume>
            <issue>11</issue>
            <fpage>1249</fpage>
            <page-range>1249-1253</page-range>
            <pub-id pub-id-type="pmid">31256368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21989.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Slamon</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Neven</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fasching</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>De Laurentiis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Im</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Petrakova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bianchi</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Esteva</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nusch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sonke</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>De la Cruz-Merino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Pivot</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Sondhi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chakravartty</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rodriguez-Lorenc</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Taran</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jerusalem</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Feb</month>
            <day>06</day>
            <volume>382</volume>
            <issue>6</issue>
            <fpage>514</fpage>
            <page-range>514-524</page-range>
            <pub-id pub-id-type="pmid">31826360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21989.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turner</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Ro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Andr&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Loi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Harbeck</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Loibl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huang Bartlett</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Giorgetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Randolph</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koehler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cristofanilli</surname>
                <given-names>M</given-names>
              </name>
              <collab>PALOMA3 Study Group</collab>
            </person-group>
            <article-title>Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Jul</month>
            <day>16</day>
            <volume>373</volume>
            <issue>3</issue>
            <fpage>209</fpage>
            <page-range>209-19</page-range>
            <pub-id pub-id-type="pmid">26030518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21989.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nathan</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>A Review of Fulvestrant in Breast Cancer.</article-title>
            <source>Oncol Ther</source>
            <year>2017</year>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-29</page-range>
            <pub-id pub-id-type="pmid">28680952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21989.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Croxtall</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>McKeage</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.</article-title>
            <source>Drugs</source>
            <year>2011</year>
            <month>Feb</month>
            <day>12</day>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>363</fpage>
            <page-range>363-80</page-range>
            <pub-id pub-id-type="pmid">21319872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21989.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bross</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Pazdur</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>FDA drug approval summaries: fulvestrant.</article-title>
            <source>Oncologist</source>
            <year>2002</year>
            <volume>7</volume>
            <issue>6</issue>
            <fpage>477</fpage>
            <page-range>477-80</page-range>
            <pub-id pub-id-type="pmid">12490735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21989.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morales-Conde</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Ib&#x000e1;&#x000f1;ez</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Calvete-Candenas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mendon&#x000e7;a</surname>
                <given-names>FMI</given-names>
              </name>
            </person-group>
            <article-title>Fulvestrant-induced toxic epidermal necrolysis.</article-title>
            <source>An Bras Dermatol</source>
            <year>2019</year>
            <season>Mar-Apr</season>
            <volume>94</volume>
            <issue>2</issue>
            <fpage>218</fpage>
            <page-range>218-220</page-range>
            <pub-id pub-id-type="pmid">31090829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21989.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vergote</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.</article-title>
            <source>Br J Cancer</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>90 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>S11</fpage>
            <page-range>S11-4</page-range>
            <pub-id pub-id-type="pmid">15094759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21989.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hawle</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thuerlimann</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer.</article-title>
            <source>Case Rep Oncol</source>
            <year>2010</year>
            <month>Apr</month>
            <day>29</day>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>131</fpage>
            <page-range>131-136</page-range>
            <pub-id pub-id-type="pmid">20740185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21989.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheung</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Fulvestrant.</article-title>
            <source>Expert Opin Investig Drugs</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>303</fpage>
            <page-range>303-8</page-range>
            <pub-id pub-id-type="pmid">11829719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21989.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robertson</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fulvestrant: pharmacokinetics and pharmacology.</article-title>
            <source>Br J Cancer</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>90 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>S7</fpage>
            <page-range>S7-10</page-range>
            <pub-id pub-id-type="pmid">15094758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21989.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gradishar</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mauriac</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bines</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Amant</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Federico</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fein</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Romieu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Buzdar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Brufsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Possinger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rennie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sapunar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lowe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Piccart</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.</article-title>
            <source>J Clin Oncol</source>
            <year>2008</year>
            <month>Apr</month>
            <day>01</day>
            <volume>26</volume>
            <issue>10</issue>
            <fpage>1664</fpage>
            <page-range>1664-70</page-range>
            <pub-id pub-id-type="pmid">18316794</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
